HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Sept. 19, 2006--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced positive efficacy and safety results from its recently completed Phase 2 trial of NX-1207 for benign prostatic hyperplasia (BPH). 43 clinical trial sites across the U.S. and 175 subjects participated in the double-blind, placebo controlled trial.
